Dyadic Logo Current.jpg
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
February 28, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Global Nucleic Acid Isolation and Purification Market
Global Nucleic Acid Isolation and Purification Research 2023-2030: Growth Opportunities in Emerging Economies and Improving Regulatory and Reimbursement Scenario
January 03, 2024 06:23 ET | Research and Markets
Dublin, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The "Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid...
Dyadic Logo Current.jpg
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023 08:30 ET | Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Hugo_Fry_by_Barry_Braunstein_Photography
20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer to Expedite mRNA Vaccine Delivery Platform Program
November 29, 2023 03:00 ET | 20MED Therapeutics B.V.
Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer. His appointment...
Dyadic Logo Current.jpg
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
November 20, 2023 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Logo Current.jpg
Dyadic to Present at Industry and Investor Events in October
September 29, 2023 08:30 ET | Dyadic International, Inc.
Dyadic to Present at Industry and Investor Events in October
Dyadic Logo Current.jpg
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
September 26, 2023 08:30 ET | Dyadic International, Inc.
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and...
Transparency Market Research
COVID-19 Vaccine Market Predicted to Reach USD 9.9 billion by 2031, Garnering -13.6% CAGR: TMR Report
September 14, 2023 09:30 ET | Transparency Market Research
Wilmington, Delaware, United States, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The COVID-19 vaccine market was estimated to have acquired US$ 92.6 billion in 2021. It is...
Global RNA Therapy Clinical Trials Market
RNA Therapy Clinical Trials Market Report 2023-2030: Strategies and Collaborations Shaping the Industry
August 29, 2023 04:48 ET | Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report, 2023-2030" report has been added to ResearchAndMarkets.com's offering. ...
TelesisBio_Logo_RGB.png
Telesis Bio Reports Second Quarter 2023 Financial Results
August 10, 2023 16:05 ET | Telesis Bio
SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the second...